
Jagsonpal (JAGSNPHARM) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
756.1M
Gross Profit
486.8M
64.39%
Operating Income
118.6M
15.69%
Net Income
108.0M
14.28%
EPS (Diluted)
₹1.58
Balance Sheet Metrics
Total Assets
2.8B
Total Liabilities
383.1M
Shareholders Equity
2.4B
Debt to Equity
0.16
Cash Flow Metrics
Revenue & Profitability Trend
Jagsonpal Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 2.7B | 2.1B | 2.4B | 2.2B | 1.9B |
Cost of Goods Sold | 964.4M | 801.3M | 925.1M | 892.8M | 809.3M |
Gross Profit | 1.7B | 1.3B | 1.4B | 1.3B | 1.1B |
Gross Margin % | 64.1% | 61.6% | 60.9% | 59.0% | 56.9% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | 201.4M | 234.7M | 240.5M | 172.6M |
Other Operating Expenses | 502.7M | 223.0M | 185.6M | 180.3M | 136.3M |
Total Operating Expenses | 502.7M | 424.4M | 420.3M | 420.8M | 308.9M |
Operating Income | 429.4M | 216.7M | 343.3M | 245.4M | 187.9M |
Operating Margin % | 16.0% | 10.4% | 14.5% | 11.3% | 10.0% |
Non-Operating Items | |||||
Interest Income | - | 85.9M | 34.3M | 15.5M | 29.9M |
Interest Expense | 9.6M | 7.8M | 2.8M | 2.6M | 4.3M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 698.6M | 298.7M | 348.1M | 266.4M | 218.7M |
Income Tax | 145.0M | 74.1M | 80.9M | 77.9M | 48.1M |
Effective Tax Rate % | 20.8% | 24.8% | 23.2% | 29.2% | 22.0% |
Net Income | 553.6M | 224.6M | 267.2M | 188.6M | 170.6M |
Net Margin % | 20.6% | 10.8% | 11.3% | 8.7% | 9.1% |
Key Metrics | |||||
EBITDA | 592.6M | 323.1M | 392.1M | 289.0M | 231.4M |
EPS (Basic) | ₹8.26 | ₹3.40 | ₹4.08 | ₹2.88 | ₹2.60 |
EPS (Diluted) | ₹8.22 | ₹3.38 | ₹4.08 | ₹2.88 | ₹2.60 |
Basic Shares Outstanding | 67023123 | 66123627 | 65495000 | 65495000 | 65495000 |
Diluted Shares Outstanding | 67023123 | 66123627 | 65495000 | 65495000 | 65495000 |
Income Statement Trend
Jagsonpal Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 112.2M | 127.6M | 110.5M | 225.3M | 589.4M |
Short-term Investments | 1.2B | 1.4B | 1.0B | 248.8M | 52.3M |
Accounts Receivable | 131.8M | 109.5M | 208.7M | 155.8M | 126.6M |
Inventory | 152.0M | 150.0M | 206.8M | 297.4M | 297.2M |
Other Current Assets | 40.2M | 80.8M | 80.7M | -81.0K | 120.6M |
Total Current Assets | 1.6B | 2.0B | 1.6B | 1.1B | 1.2B |
Non-Current Assets | |||||
Property, Plant & Equipment | 88.4M | 83.9M | 59.3M | 223.7M | 233.5M |
Goodwill | 953.1M | - | 0 | 600.0K | 600.0K |
Intangible Assets | 759.2M | - | - | 23.5M | 23.5M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 44.2M | 21.1M | 20.3M | 29.2M | 8.4M |
Total Non-Current Assets | 1.2B | 178.2M | 303.9M | 551.4M | 461.9M |
Total Assets | 2.8B | 2.2B | 1.9B | 1.6B | 1.6B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 97.3M | 76.0M | 165.8M | 185.5M | 206.8M |
Short-term Debt | 16.1M | 13.8M | 7.5M | 0 | 67.9M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 32.0M | 1.0M | 1.4M | 230.0K | 44.3M |
Total Current Liabilities | 259.0M | 191.3M | 275.7M | 269.7M | 375.8M |
Non-Current Liabilities | |||||
Long-term Debt | 76.3M | 75.6M | 52.5M | 0 | 0 |
Deferred Tax Liabilities | 30.7M | 20.7M | 21.6M | 32.4M | 23.4M |
Other Non-Current Liabilities | - | - | - | - | - |
Total Non-Current Liabilities | 124.1M | 105.5M | 84.8M | 44.9M | 23.5M |
Total Liabilities | 383.1M | 296.8M | 360.6M | 314.7M | 399.4M |
Equity | |||||
Common Stock | 132.8M | 132.2M | 131.0M | 131.0M | 131.0M |
Retained Earnings | - | 1.0B | 945.4M | 693.7M | 585.9M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 2.4B | 1.9B | 1.6B | 1.3B | 1.2B |
Key Metrics | |||||
Total Debt | 92.4M | 89.4M | 60.0M | 0 | 67.9M |
Working Capital | 1.4B | 1.8B | 1.4B | 821.1M | 810.4M |
Balance Sheet Composition
Jagsonpal Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 698.6M | 298.7M | 348.1M | 266.4M | 218.7M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 68.0M | 133.1M | 87.6M | 0 | - |
Working Capital Changes | 30.0M | 143.0M | 117.5M | -97.3M | 136.8M |
Operating Cash Flow | 532.9M | 497.0M | 550.9M | 156.5M | 333.6M |
Investing Activities | |||||
Capital Expenditures | 353.7M | -2.5M | 9.8M | -4.7M | -4.7M |
Acquisitions | -936.6M | - | - | - | - |
Investment Purchases | -2.6B | -1.4B | -1.1B | -284.5M | -41.7M |
Investment Sales | 2.6B | 1.0B | 438.2M | - | - |
Investing Cash Flow | -529.9M | -319.2M | -611.0M | -289.2M | -46.4M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -132.3M | -131.0M | - | -104.8M | -26.2M |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | 0 | -67.9M | - |
Financing Cash Flow | -98.4M | -74.6M | -3.2M | -240.5M | -26.2M |
Free Cash Flow | 549.5M | 349.2M | 463.4M | 58.6M | 277.5M |
Net Change in Cash | -95.3M | 103.2M | -63.3M | -373.2M | 260.9M |
Cash Flow Trend
Jagsonpal Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
27.17
Price to Book
6.86
Price to Sales
5.78
PEG Ratio
0.26
Profitability Ratios
Profit Margin
21.50%
Operating Margin
15.69%
Return on Equity
23.07%
Return on Assets
19.90%
Financial Health
Current Ratio
6.22
Debt to Equity
3.85
Beta
0.24
Per Share Data
EPS (TTM)
₹9.02
Book Value per Share
₹35.72
Revenue per Share
₹42.34
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
jagsnpharm | 16.4B | 27.17 | 6.86 | 23.07% | 21.50% | 3.85 |
Sun Pharmaceutical | 3.9T | 37.88 | 5.45 | 15.08% | 19.29% | 3.26 |
Divi's Laboratories | 1.6T | 70.42 | 10.88 | 14.64% | 23.89% | 0.03 |
Sun Pharma Advanced | 45.5B | -13.34 | -21.04 | 157.88% | -53.22% | -1.24 |
Aarti Drugs | 44.4B | 23.59 | 3.25 | 12.28% | 7.80% | 44.92 |
Sequent Scientific | 43.9B | 154.18 | 6.24 | 2.84% | 1.85% | 62.47 |
Financial data is updated regularly. All figures are in the company's reporting currency.